바이오뱅크 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 바이오 샘플 유형별, 바이오뱅크 유형별, 서비스별, 용도별, 지역별, 부문별 예측(2026-2033년)
Biobanks Market Size, Share & Trends Analysis Report By Product & Services (LIMS, Biobanking Equipment), By Biospecimen Type (Organs, Stem Cells), By Biobank Type (Real, Virtual), By Service, By Application, By Region, And Segment Forecasts, 2026 - 2033
상품코드
:
1908491
리서치사
:
Grand View Research
발행일
:
2025년 12월
페이지 정보
:
영문 150 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
바이오뱅크 시장 개요
세계의 바이오뱅크 시장 규모는 2025년에 868억 2,000만 달러로 추정되며, 2033년에 1,605억 4,000만 달러에 달할 것으로 예측됩니다.
2026-2033년에는 CAGR 8.11%로 성장할 것으로 예상됩니다. 재생의료, 맞춤의료, 암 유전체 연구 등 첨단 치료법에 대한 연구개발에 대한 막대한 투자가 주요 촉진요인 중 하나입니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 바이오뱅크 시장 변수, 동향과 범위
시장 계보 전망
시장 역학
바이오뱅크 시장 분석 툴
산업 분석 : Porter's Five Forces
PESTEL 분석
제4장 바이오뱅크 시장 : 제품 및 서비스별, 추정·동향 분석
제품 및 서비스별 시장 점유율(2025년과 2033년)
제품
시장 규모 및 예측과 동향 분석(2021-2033년)
바이오뱅크 장비
바이오뱅크 소모품
실험실 정보 관리 시스템
서비스
시장 규모 및 예측과 동향 분석(2021-2033년)
바이오뱅크와 리포지토리
실험실 처리
적격성 평가/밸리데이션
콜드체인 물류
기타
제5장 바이오뱅크 시장 : 바이오 샘플 유형별, 추정·동향 분석
바이오 샘플 유형별 시장 점유율(2025년과 2033년)
시장 규모, 예측, 동향 분석(2021-2033년)
인간 조직
인간 장기
줄기세포
기타 바이오 샘플
제6장 바이오뱅크 시장 : 바이오뱅크 유형별, 추정·동향 분석
바이오뱅크 유형별 시장 점유율(2025년과 2033년)
시장 규모 및 예측과 동향 분석(2021-2033년)
제7장 바이오뱅크 시장 : 용도별, 추정·동향 분석
용도별 시장 점유율(2025년과 2033년)
시장 규모 및 예측과 동향 분석(2021-2033년)
치료
Drug Discovery·임상 연구
임상 진단
기타
제8장 바이오뱅크 시장 : 지역별, 추정·동향 분석
지역별 시장 대시보드
지역별 시장 점유율 분석(2025년과 2033년)
시장 규모와 예측 동향 분석, 2021-2033년
북미
유럽
영국
독일
프랑스
이탈리아
스페인
노르웨이
스웨덴
덴마크
아시아태평양
라틴아메리카
중동 및 아프리카
남아프리카공화국
사우디아라비아
아랍에미리트
쿠웨이트
제9장 경쟁 구도
기업/경쟁 분류
전략 매핑
2025년의 기업 시장 상황 분석
기업 개요/리스트
Thermo Fisher Scientific Inc.
Merck KGaA
Qiagen
Hamilton Company
Tecan Trading AG
Danaher Corporation
Becton, Dickinson, and Company(BD)
Biocision, LLC.
Taylor-Wharton
Charles River Laboratories
Lonza
Stemcell Technologies
Biovault Family
Promocell Gmbh
Precision Cellular Storage Ltd.(Virgin Health Bank)
KSM
영문 목차
Biobanks Market Summary
The global biobanks market size was estimated at USD 86.82 billion in 2025 and is anticipated to reach USD 160.54 billion by 2033, growing at a CAGR of 8.11% from 2026 to 2033. High investments in the R&D of advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, are some of the driving factors.
Global Biobanks Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biobanks market report based on product & service, biospecimen type, biobank type, application, and region:
Product & Services Outlook (Revenue, USD Million, 2021 - 2033)
Product
Biobanking Equipment
Temperature Control Systems
Freezers & Refrigerators
Cryogenic Storage Systems
Thawing Equipment
Incubators & Centrifuges
Alarms & Monitoring Systems
Accessories & Other Equipment
Biobanking Consumables
Laboratory Information Management Systems
Services
Biobanking & Repository
Lab processing
Qualification/ Validation
Cold Chain Logistics
Other Services
Biospecimen Type Outlook (Revenue, USD Million, 2021 - 2033)
Human Tissues
Human Organs
Stem Cells
Adult Stem Cells
Embryonic Stem Cells
IPS Cells
Other Stem Cells
Other Biospecimens
Biobank Type Outlook (Revenue, USD Million, 2021 - 2033)
Physical/Real Biobanks
Tissue Biobanks
Population-Based Biobanks
Genetic (DNA/RNA)
Disease-Based Biobanks
Virtual Biobanks
Application Type Outlook (Revenue, USD Million, 2021 - 2033)
Therapeutics
Drug Discovery & Clinical Research
Clinical Diagnostics
Other Applications
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
Germany
UK
France
Spain
Italy
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Latin America
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product & Services
1.2.2. Biospecimen Type
1.2.3. Biobank Type
1.2.4. Application
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biobanks Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increased focus on precision medicine and genetic testing
3.2.1.2. Changes in biobanking operations
3.2.1.3. Increase in the number of clinical trials globally
3.2.1.4. Growing industry and research collaborations
3.2.1.5. Technology advancement and automation
3.2.2. Market restraint analysis
3.2.2.1. Challenges in sharing biobanking data & limited access to biospecimens
3.2.2.2. Sustainability challenges for biobanks
3.2.2.3. Other challenges in biobanking specimens for research
3.3. Biobanks Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
Chapter 4. Biobanks Market: Product & Services Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Product & Services Market Share, 2025 & 2033
4.3. Product
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
4.4.1. Biobanking Equipment
4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.2. Temperature Control Systems
4.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.2.2. Freezers & Refrigerators
4.4.1.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.2.3. Cryogenic Storage Systems
4.4.1.2.4. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.2.5. Thawing Equipment
4.4.1.2.6. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.3. Incubators & Centrifuges
4.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.4. Alarms & Monitoring Systems
4.4.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.1.5. Accessories & Other Equipment
4.4.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. Biobanking Consumables
4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. Laboratory Information Management Systems
4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Services
4.6. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.6.1. Biobanking & repository
4.6.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.6.2. Lab processing
4.6.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.6.3. Qualification/ Validation
4.6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.6.4. Cold Chain Logistics
4.6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.6.5. Other Services
4.6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Biobanks Market: Biospecimen Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Biospecimen Type Market Share, 2025 & 2033
5.3. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
5.3.1. Human Tissues
5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.3.2. Human Organs
5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.3.3. Stem Cells
5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.3.3.2. Adult Stem Cells
5.3.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.3.3.3. Embryonic Stem Cells
5.3.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.3.3.4. IPS Cells
5.3.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.3.3.5. Other Stem Cells
5.3.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.3.4. Other biospecimens
5.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Biobanks Market: Biobank Type Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Biobank Type Market Share, 2025 & 2033
6.3. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
6.3.1. Physical/Real biobanks
6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.3.1.2. Tissue Biobanks
6.3.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.3.1.3. Population-based biobanks
6.3.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.3.1.4. Genetic (DNA/RNA)
6.3.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.3.1.5. Disease-Based biobanks
6.3.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
6.3.2. Virtual biobanks
6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Biobanks Market: Application Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Application Market Share, 2025 & 2033
7.3. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
7.3.1. Therapeutics
7.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
7.3.2. Drug discovery & clinical research
7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
7.3.3. Clinical Diagnostics
7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
7.3.4. Other Applications
7.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Biobanks Market: Regional Estimates & Trend Analysis
8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2025 & 2033
8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033
8.4. North America
8.4.1. U.S.
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework
8.4.1.3. Competitive scenario
8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
8.4.2. Canada
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework
8.4.2.3. Competitive scenario
8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
8.4.3. Mexico
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework
8.4.3.3. Competitive scenario
8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Europe
8.5.1. UK
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework
8.5.1.3. Competitive scenario
8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
8.5.2. Germany
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework
8.5.2.3. Competitive scenario
8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
8.5.3. France
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework
8.5.3.3. Competitive scenario
8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
8.5.4. Italy
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework
8.5.4.3. Competitive scenario
8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
8.5.5. Spain
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework
8.5.5.3. Competitive scenario
8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
8.5.6. Norway
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework
8.5.6.3. Competitive scenario
8.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
8.5.7. Sweden
8.5.7.1. Key country dynamics
8.5.7.2. Regulatory framework
8.5.7.3. Competitive scenario
8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
8.5.8. Denmark
8.5.8.1. Key country dynamics
8.5.8.2. Regulatory framework
8.5.8.3. Competitive scenario
8.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Japan
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework
8.6.1.3. Competitive scenario
8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
8.6.2. China
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework
8.6.2.3. Competitive scenario
8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
8.6.3. India
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework
8.6.3.3. Competitive scenario
8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
8.6.4. Australia
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework
8.6.4.3. Competitive scenario
8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
8.6.5. South Korea
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework
8.6.5.3. Competitive scenario
8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
8.6.6. Thailand
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework
8.6.6.3. Competitive scenario
8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
8.7. Latin America
8.7.1. Brazil
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework
8.7.1.3. Competitive scenario
8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
8.7.2. Argentina
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework
8.7.2.3. Competitive scenario
8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
8.8. MEA
8.8.1. South Africa
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework
8.8.1.3. Competitive scenario
8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
8.8.2. Saudi Arabia
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework
8.8.2.3. Competitive scenario
8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
8.8.3. UAE
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework
8.8.3.3. Competitive scenario
8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
8.8.4. Kuwait
8.8.4.1. Key country dynamics
8.8.4.2. Regulatory framework
8.8.4.3. Competitive scenario
8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2025
9.4. Company Profiles/Listing
9.4.1. Thermo Fisher Scientific Inc.
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Merck KGaA
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Qiagen
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Hamilton Company
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Tecan Trading AG
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Danaher Corporation
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Becton, Dickinson, and Company (BD)
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Biocision, LLC.
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Taylor-Wharton
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Charles River Laboratories
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.4.11. Lonza
9.4.11.1. Company overview
9.4.11.2. Financial performance
9.4.11.3. Product benchmarking
9.4.11.4. Strategic initiatives
9.4.12. Stemcell Technologies
9.4.12.1. Company overview
9.4.12.2. Financial performance
9.4.12.3. Product benchmarking
9.4.12.4. Strategic initiatives
9.4.13. Biovault Family
9.4.13.1. Company overview
9.4.13.2. Financial performance
9.4.13.3. Product benchmarking
9.4.13.4. Strategic initiatives
9.4.14. Promocell Gmbh
9.4.14.1. Company overview
9.4.14.2. Financial performance
9.4.14.3. Product benchmarking
9.4.14.4. Strategic initiatives
9.4.15. Precision Cellular Storage Ltd. (Virgin Health Bank)
9.4.15.1. Company overview
9.4.15.2. Financial performance
9.4.15.3. Product benchmarking
9.4.15.4. Strategic initiatives
관련자료
